|Bid||0.2655 x 40700|
|Ask||0.2800 x 1100|
|Day's range||0.2610 - 0.2889|
|52-week range||0.2500 - 6.7800|
|Beta (5Y monthly)||0.08|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.88|
BURLINGTON, Mass., October 25, 2022--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick.
BURLINGTON, Mass., October 12, 2022--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced underwritten public offering of units of securities for total gross proceeds of $5,100,000, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company plans to use the net proceeds to fund its planned clinical trials, maintain and extend its patent por
BURLINGTON, Mass., October 07, 2022--Reissuing release to remove "million" after "$5,100,000" in the headline and first sentence of the text.